Abstract
One of the new approaches to the management of type 2 diabetes mellitus (T2DM) consists of orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitors. These synthetic drug inhibitors are reported to have some side effects and that subsequently limits their applications. There is a growing interest to develop natural DPP-IV inhibitors that will be potent without undesirable side effects. Many in vitro and some in vivo studies have highlighted the potential of food-derived peptides functioning as effective DPPIV inhibitors. Bioactive peptides within original food-derived proteins are inactive but can be activated by being released during food processing (by enzymatic hydrolysis or fermentation) or during gastrointestinal digestion. Hence, the utilization of computer-aided techniques as screening tools may be helpful in predicting the potential of food proteins as precursors of DPP-IV inhibitory peptides. This paper reviews the current literature on DPP-IV inhibitory peptides, focusing on their in vitro activity and in vivo antidiabetic effects. In addition, the feasibility of various in silico approaches is also summarized in this review.
Highlights
Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disorder that is characterized by insulin insensitivity as a result of impaired insulin secretion, insulin resistance, and eventual pancreatic beta-cell failure [1, 2]
There are two major in silico approaches: the frequency of the occurrence of bioactive peptides within a dietary protein [37], and binding modes by docking analysis [27]. The former is calculated as the number of previously identified bioactive peptides that are found in a given dietary protein; the simulation of protein hydrolysis by a bioinformatics tool, e.g. BIOPEP database and program, to find peptides that can be released by a given enzyme is efficient to classify proteins as potential sources of bioactive fragments [36]
The importance and scientific understanding of dipeptidyl peptidase-IV (DPP-IV) inhibitors that may improve glycemic control in T2DM patients has increased in the last few decades
Summary
Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disorder that is characterized by insulin insensitivity as a result of impaired insulin secretion, insulin resistance, and eventual pancreatic beta-cell failure [1, 2]. The former is calculated as the number of previously identified bioactive peptides that are found in a given dietary protein; the simulation of protein hydrolysis by a bioinformatics tool, e.g. BIOPEP database and program, to find peptides that can be released by a given enzyme is efficient to classify proteins as potential sources of bioactive fragments [36] The latter, the ligandenzyme and molecular docking analysis, can simulate the binding and interactions between peptides and enzymes such as DPP-IV and ACE in order to evaluate the inhibitory effects of the peptides [27].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
